Navigation Links
DermBiont Announces Positive Data from Phase 2a Clinical Trial and Start of Phase 2b Clinical Trial for Athlete’s Foot with a Topical Live Biotherapeutic

DermBiont, a clinical stage microbiome biotechnology company developing topical live biotherapeutics, has announced that its lead program, DBI-001, met its primary safety endpoints, with no application site reactions and no adverse events, in a 12 person open labeled phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s foot). Additionally, the trial demonstrated a clinical response with improvement in the signs and symptoms of tinea pedis and demonstrated a reduction in the abundance of Trichophyton rubrum.

Based on the results of the completed phase 2a trial, the company has started enrolling patients in a phase 2b clinical trial, which is a double-blind placebo-controlled study for the treatment of interdigital tenia pedis. The company will also be initiating a clinical trial in onychomycosis in early 2020.

In addition to addressing tinea pedis, DermBiont’s lead candidate, DBI-001, is being evaluated for additional indications related to bacterial infection of the skin. In-vitro, DBI-001 has activity against fungi as well as bacteria. “This was DermBiont’s first clinical trial, and it is rewarding to have met our goals for the study and enabled additional clinical trials. Although primarily designed as a safety study, our team is excited to see signs of a therapeutic response from a single dose of our product,” said Dr. Karl Beutner, CEO of DermBiont.

“We continue to be pleased with the progress of our lead program along with other ongoing discovery and clinical efforts,” added Dr. Robert Brucker, the company’s CSO.

Approximately 15-25% of individuals globally are afflicted with athlete’s foot and about 70% of the global population will suffer from athlete’s foot at least once. There is an unmet clinical need for a therapeutic treatment that addresses the root cause of athlete’s foot, a dysbiosis of the microbiome, and cures this otherwise chronic and recurrent condition. With the success of its ongoing program, DermBiont plans to commercialize the first FDA approved topical live biotherapeutic to treat skin disease.

About DermBiont

DermBiont is a dermatology company leveraging skin microbiome therapeutics to treat the root cause of skin diseases. In addition to advancing DBI-001, the company has a discovery platform based on a library of thousands of microbes isolated from human skin and one of the world’s largest data sets of Nextgen sequencing of the human microbiome across healthy and diseased skin.

Send all inquiries to:

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. R3 Stem Cell Announces Addition of World Renowned Exosome Expert Dr. Ian White to Training Course
2. Cereset® Announces Mild-Traumatic Brain Injury Focused Clinical Trial Progress
3. Personalized Stem Cells, Inc. Announces Clinical Trial Sites Qualified for FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
4. Advancements Announces New Episode Focusing on Innovations in Health, Medicine, and Technology
5. Shoreline Biome Announces International Distribution Partnerships
6. Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
7. Trivedi Global, Inc. Announces Research by Alice Branton on the Benefits of Trivedi Effect® Energy Treated Magnesium Gluconate
8. Leak Detection Associates Announces Expansion to Chinese Market – Partnership Agreement Signed With Shanghai Zillion
9. Object Pharma Announces Strategic Acquisition of Metabiologics
10. Milton Hershey School Announces 2019 Alumnus of the Year
11. Leak Detection Associates Announces Release of New Website
Post Your Comments:
(Date:11/12/2019)... ... November 12, 2019 , ... ... the food and beverage industry launched a new innovative website. , After extensive ... Now, the website offers global visitors updated ingredient usage tables by food application ...
(Date:11/6/2019)... ... ... Diversified Technologies, Inc. has introduced a PEF production system for ... processing. , The DTI Industrial PEF Unit can pre-treat whole pieces of fruits and ... up to 50% and achieve up to an 80% reduction of drying energy. ...
(Date:11/5/2019)... ... ... was demonstrating signs of osteoarthritis in April 2019. He was lame and stiff and ... play were normal, it was clear that he was in pain. , Ole’s owner took ... Center in San Diego, California. Dr. Mullen is an experienced VetStem user and ...
(Date:10/30/2019)... ... October 30, 2019 , ... While using cold plasma to kill cancer cells ... Dakota School of Mines & Technology are exploring new ways to regulate cold ... , If successful, the technique would prove to be a drug-free, minimally invasive cancer ...
Breaking Biology Technology:
(Date:11/5/2019)... , ... November 05, 2019 , ... ... manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced ... at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019. , On ...
(Date:10/30/2019)... Va. (PRWEB) , ... October 30, 2019 , ... ... offering from the Farm Credit Knowledge Center in which participants will learn about ... industry best practice relating to these technologies. , Participants will have the ...
(Date:10/29/2019)... ... October 29, 2019 , ... ... announced that Octapharma, one of the world’s largest human protein manufacturers, has ... manufacturing of therapeutic proteins addressing severe diseases in the areas of haematology, ...
Breaking Biology News(10 mins):